Small dense LDL cholesterol and coronary heart disease: Results from the Framingham offspring study

Clinical Chemistry

Volumn 56, Issue 6, 2010, Pages 967-976

  Ai, Masumi ^a   Otokozawa, Seiko ^a   Asztalos, Bela F ^a   Ito, Yasuki ^b   Nakajima, Katsuyuki ^a   White, Charles C ^c   Cupples, L Adrienne ^c   Wilson, Peter W ^d,e   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b Research and Development Department   (Japan)

^c BOSTON UNIVERSITY   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; REFERENCE VALUE; SEX DIFFERENCE;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; COHORT STUDIES; CORONARY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTMENOPAUSE;

EID: 77953011625     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.137489     Document Type: Article

References (37)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Cholesterol Treatment Trialists Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267-1278
2. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006;48: 438-445 (Pubitemid 44109954)
3. Campos H, Genest JJ Jr, Blijlevens E, McNamara JR, Jenner J, Ordovas JM, et al. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992;12:187-195
4. Coresh J, Kwiterovich PO Jr. Small, dense low-density lipoprotein particles and coronary heart disease risk: a clear association with uncertain implications. [Editorial] JAMA 1996;276:914-915
5. Chapman MJ, Bruckert E. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy. Atherosclerosis 1996;124(Suppl):S21-8.
6. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882-888 (Pubitemid 26301607)
7. Austin MA, Breslow JL, Hennekens GH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-1921
8. Kathiresan S, Otvos JD, Sullivan LM, Keys MJ, Schaefer EJ, Wilson PW, et al. Increased small low density lipoprotein particle number: a prominent feature of metabolic syndrome in the Framingham Heart Study. Circulation 2006;113:20-29 (Pubitemid 43958484)
9. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Robins SJ. Lowdensity lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-1563 (Pubitemid 43739414)
10. Hirano T, Ito Y, Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb 2005;12:67-72.
11. Hirano T, Ito Y, Saegusa H, Yoshino G. A novel and simple method for quantification of small dense low-density lipoprotein. J Lipid Res 2003; 44:2193-2201 (Pubitemid 37509635)
12. Hirano T, Ito Y, Koba S, Toyoda M, Ikejiri A, Saegusa H, et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arterioscler Thromb Vasc Biol 2004;24:558-563 (Pubitemid 38326153)
13. Koba S, Hirano T, Ito Y, Tsunoda F, Yokota Y, Ban Y, et al. Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases. Atherosclerosis 2006;189:206-214 (Pubitemid 44441285)
14. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847 (Pubitemid 28213628)
15. McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results of the Framingham offspring study. Arteriosclerosis 1987;7:483-490
16. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ. High density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants in the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004;24:2181-2187
17. 2+ precipitation Procedure for Quantitation of high-density- lipoprotein cholesterol. Clin Chem 1982;28:1379-1388
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18: 499-502.
19. Campos H, Blijlevens E, McNamara JR, Ordvoas JM, Wilson PWF, Schaefer EJ. LDL particle size distribution: results from the Framingham Offspring Study. Arterioscler Thromb 1992; 1992;12: 1410-1419
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497
21. St. Pierre AC, Cantin B, Dagenais GR, Mauriega P, Bernard PM, Depres JP, Lamarche B. Low density lipoprotein subfractions and long term risk of heart disease in men: 13 year followup data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25:474-479
22. Mora S, Szklo M, Otvos JD, Greenland P, Psaty BM, Goff DC Jr, et al. Low density lipoprotein subclasses, low density lipoprotein particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007;192:211-217
23. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, McNamara JR, Robins SJ. Lowdensity lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-1563 (Pubitemid 43739414)
24. Musunuru K, Orth-Melander M, Caulfield MP, Li S, Salameh WA, Reitz RE, et al. Ion mobility analysis of lipoprotein subfractions indicate three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol 2009;29:1975-1980
25. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, et al. Effects of consuming fructose- or glucose-sweetened beverages for 10 weeks on lipids, insulin sensitivity and adiposity. J Clin Invest 2009;119:1322-1334
26. Vega-López S, Matthan NR, Ausman LM, Ai M, Otokozawa S, Schaefer EJ, Lichtenstein AH. Substitution of vegetable oil for a partiallyhydrogenated fat favorably alters cardiovascular disease risk factors in moderately hypercholesterolemic postmenopausal women. Atherosclerosis 2009;207:208-212
27. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. JUPITER Trial Study Group. Reduction in C reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373: 1175-1182
28. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-1565
29. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, Schaefer EJ. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants in the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004;24:2181-2187
30. Asztalos BF, Collins D, Cupples LA, Demissie S, Horvath KV, Bloomfield HE, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005;25:2185-2191
31. Asztalos BF, Batista M, Horvath KV, Cox CE, Dallal GE, Morse JS, et al. Change in alpha 1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003;23:847-852
32. Ai M, Otokozawa S, Asztalos BF, Nakajima K, Stein EA, Jones PH, Schaefer EJ. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low density lipoprotein cholesterol levels. Am J Cardiol 2008;101:315-318
33. Asztalos BF, LeMaulf F, Dallal GE, Stein E, Jones PH, Horvath KV, et al. Comparison of the effects of high doses of rosuvastatin versus atorvastatin on the subpopulations of high density lipoproteins. Am J Cardiol 2007;99:681-685
34. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, Wilson PWF. Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 1994;35:779-792 (Pubitemid 24157230)
35. Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS, Schaefer EJ. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100. J Lipid Res 1995;36:1155-1167
36. Matthan N, Jalbert SM, Lamon-Fava S, Dolnikowski GG, Welty FK, Barrett PHR, et al. TRL, IDL, and LDL apolipoprotein B-100 and HDL apolipoprotein A-I kinetics as a function of age and menopausal status. Arterioscler Thromb Vasc Biol 2005;25:1691-1696
37. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298:776-785